Published in Healthcare Mergers, Acquisitions and Ventures Week, January 20th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Uroplasty.
Report 1: Uroplasty, Inc. (UPI) announced that it received from the U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for its Macroplastique Implants. With this approval, Uroplasty can begin marketing Macroplastique in the United States for the treatment of female stress urinary incontinence primarily due to intrinsic sphincter deficiency.
Following market introduction, the company will conduct customary, FDA-required post approval studies to obtain market...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.